

# Acanthosis Nigricans

[View the current Acanthosis Nigricans InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Acanthosis_Nigricans.html) ([PDF](#))

([http://www.bioportfolio.com/indepth/Acanthosis\\_Nigricans.html](http://www.bioportfolio.com/indepth/Acanthosis_Nigricans.html)) - Regularly Updated.

## Recent Publications on Acanthosis Nigricans:



- [Body mass index as a surrogate measure of cardiovascular risk factor clustering in fifth-grade children: Results from the coronary artery risk detection in the Appalachian Communities Project.](#)  
*Background. Obesity, an increasing problem in children in the United...*20th November, 2009  
West Virginia University.- Int J Pediatr Obes. 2009;4(4):316-324.
- [Insulin resistance and overweight-obese women with polycystic ovary syndrome.](#)  
*Aim. To estimate (1) the prevalence of insulin resistance (IR) by fasting...*12th November, 2009  
S. C. Das Memorial Medical & Research Center, Kolkata, India.- Gynecol Endocrinol. 2009 Nov 11.
- [Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism.](#)  
*Abstract Objective. To investigate biochemical and metabolic abnormalities...*11th November, 2009  
Department of Gynecology and Obstetrics.- Acta Obstet Gynecol Scand. 2009 Nov 10.
- [\[Skin manifestations, treatment and rehabilitation in overweight and obesity\]](#)  
*Overweight and obesity is a public health problem in Hungary and in the...*31st October, 2009  
Fovarosí Onkormányzat Egyesített Szent István és Szent László Korház és- Orv Hetil. 2009 Sep 13;150(37):1731-8. ([DOI Direct Link](#))
- [Hypodontia in Beare-Stevenson Syndrome: An Example of Dental Anomalies in FGFR-related Craniosynostosis Syndromes.](#)  
*We report a new case of Beare-Stevenson syndrome characterized by cutis...*29th October, 2009  
- Cleft Palate Craniofac J. 2009 Oct 19:1. ([DOI Direct Link](#))
- [\[Fatty liver disease, insulin resistance and adiponectin in an obese pediatric population.\]](#)  
*INTRODUCTION: To study the clinical and laboratory relationships of fatty...*24th October, 2009  
Unidad de Endocrinología Pediátrica, Servicio de Pediatría, Hospital La- An Pediatr (Barc). 2009 Dec;71(6):495-501. Epub 2009 Oct 21. ([DOI Direct Link](#))
- [Metformin, Estrogen Replacement Therapy and Gonadotropin Inhibition Fail to Improve Insulin Sensitivity in a Girl with Aromatase Deficiency.](#)  
*Background: Insulin resistance (IR), abnormal lipid profile, and other...*22nd October, 2009  
Endocrine Service, Hospital de Pediatría Garrahan, Buenos Aires,- Horm Res. 2009 Oct 21;72(6):370-376. ([DOI Direct Link](#))
- [\[Presence of metabolic syndrome among patients with type 7 diabetes mellitus\]](#)  
*BACKGROUND: Metabolic Syndrome (MS) is related to insulin resistance and...*6th October, 2009  
Departamento de Endocrinología, Servicio de Medicina Interna, Hospital Dr.- Rev Med Chil. 2009 Jul;137(7):888-93. Epub 2009 Sep 24. ([DOI Direct Link](#))
- [Acanthosis Nigricans Identifies Youth at High Risk for Metabolic Abnormalities.](#)

*OBJECTIVE: To determine the prevalence of abnormal glucose homeostasis and...*3rd October, 2009  
Division of Endocrinology, Children's Memorial Hospital (W.B.) and the- J Pediatr. 2009 Sep 29. ([DOI Direct Link](#))

- [\[Adenocarcinoma of gallbladder revealed by acanthosis nigricans\]](#)

*OBJECTIVE: To determine the prevalence of abnormal glucose homeostasis and...*22nd September, 2009

- Gastroenterol Clin Biol. 2009 Oct-Nov;33(10-11):986-8. Epub 2009 Sep 17. ([DOI Direct Link](#))

- [Prevalence of acanthosis nigricans and its correlates in a cross-section of Nigerians with type 2 diabetes mellitus.](#)

*Acanthosis nigricans (AN) is a dermatological condition that is often...*19th September, 2009  
Department of Medicine, Lagos State University Teaching Hospital, Ikeja,- Trop Doct. 2009 Oct;39(4):235-6. ([DOI Direct Link](#))

- [Lipodystrophy: an unusual diagnosis in a case of oligomenorrhea and hirsutism.](#)

*BACKGROUND: Familial partial lipodystrophy, Dunnigan variety, is a rare...*16th September, 2009  
Exempla Saint Joseph Hospital, Denver, Colorado, USA.- Obstet Gynecol. 2009 Aug;114(2 Pt 2):427-31. ([DOI Direct Link](#))

- [Malignant acanthosis nigricans with enhanced expression of fibroblast growth factor receptor 3.](#)

*Overweight and obesity is a public health problem in Hungary and in the...*15th September, 2009  
- Acta Derm Venereol. 2009;89(4):435-7. ([DOI Direct Link](#))

- [Acanthosis Nigricans and Oral Glucose Tolerance in Obese Children.](#)

*Overweight and obesity is a public health problem in Hungary and in the...*27th August, 2009  
- Clin Pediatr (Phila). 2009 Aug 25. ([DOI Direct Link](#))

- [Juvenile generalized acanthosis nigricans without any systemic disease.](#)

*Overweight and obesity is a public health problem in Hungary and in the...*14th August, 2009  
Ankara Numune Education and Research Hospital, Ankara, Turkey.- Pediatr Int. 2009 Aug;51(4):595-7. ([DOI Direct Link](#))

## BioNews Results for Acanthosis Nigricans

- [Skin Pictures and Images](#)

MedicineNet.com: Oct 29 2009 2:45AM Matching: acanthosis

- [Young people with acanthosis nigricans are at high risk for Type 2 diabetes](#)

MedWire News: Oct 19 2009 12:26PM Matching: acanthosis

## Acanthosis Nigricans Clinical Trials:



- [Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome](#)





## Acanthosis Nigricans Patents:

- 7122629- [Human cDNAs and proteins and uses thereof](#)
- 7223727- [GSSP4 polynucleotides and polypeptides and uses thereof](#)
- 7229966- [Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity](#)
- 7229969- [Combinations of enzyme inhibitors and the use thereof](#)
- 7256010- [Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, ATPase molecules, acyltransferase molecules, pyridoxal-phosphate dependant enzyme molecules and uses therefor](#)
- 7276481- [Method and composition for treatment of skeletal dysplasias](#)
- 7288392- [Human protein kinases and uses therefor](#)
- 7291495- [.beta.-Secretase variant](#)
- 7297774- [Use of inhibitors for the treatment of RTK-hyperfunction-induced disorders, particularly cancer](#)
- 7319139- [TAG-72 specific C.sub.H2 domain deleted antibodies](#)
- 7323196- [Pharmaceutical composition comprising extracts of radix clematidis for treating and preventing diabetes, diabetic complications, insulin resistance and insulin resistance syndrome](#)
- 7223392- [Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics](#)
- 7205312- [N-\[4-\(heteroaryl\)methyl\]phenyl\]-heteroaryl amines](#)
- 7186692- [Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity](#)
- 7135311- [Means for detecting and treating pathologies linked to FGFR3](#)
- 7138107- [Inhibition of olfactory neurosensory function to treat eating disorders and obesity](#)
- 7157426- [Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity](#)
- 7166569- [Method for the prevention of transplant rejection](#)
- 7166575- [Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity](#)
- 7169389- [Human CD154 binding molecules and treatment methods](#)
- 7179825- [Retinoic acid mimetic anilides](#)
- 7183254- [Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment](#)
- 7183415- [Quinoline compound](#)
- 7186691- [Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity](#)
- 7329529- [Ubiquitin proteases](#)
- 7332163- [Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics](#)
- 7482147- [Ubiquitin protease](#)
- 7485308- [26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses therefor](#)
- 7491516- [Dual specificity antibodies and methods of making and using](#)
- 7498416- [Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof](#)
- 7504485- [Human antibodies that bind human IL-12](#)

- 7517890- [GTPase inhibitors and methods of use](#)
- 7572776- [N-\(phosphonoalkyl\)-amino acids, derivatives thereof and compositions and methods of use](#)
- 7579352- [Retinoic acid mimetic anilides](#)
- 7601868- [Amine derivative](#)
- 7611879- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor](#)
- 7459432- [Modification of feeding behavior](#)
- 7442720- [Compositions and methods for treating diabetes](#)
- 7438906- [Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics](#)
- 7351566- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552, and 65577 molecules and uses therefor](#)
- 7359748- [Apparatus for total immersion photography](#)
- 7368527- [HADDE71 polypeptides](#)
- 7368531- [Human secreted proteins](#)
- 7371384- [Compositions and methods of using angiotensin-like 4 protein antibody](#)
- 7378433- [N-\[4-\(heteroaryl\)methyl\]phenyl\]-heteroarylamines](#)
- 7411051- [Antibodies to HDPPA04 polypeptide](#)
- 7411054- [25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor](#)
- 7429575- [N-\(phosphonoalkyl\)-amino acids, derivatives thereof and compositions and methods of use](#)
- 7435407- [Inhibition of olfactory neurosensory function to treat eating disorders and obesity](#)
- 7612181- [Dual variable domain immunoglobulin and uses thereof](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

